Eli Lilly And Company · NYSE:LLY
Eli Lilly And — Lilly ELI & — Merger or Acquisition (January 2019)
15 slides from Eli Lilly And's merger presentation, Jan 7, 2019
Slide 1: Exhibit 99.2
Exhibit 99.2Exhibit 99.2
Slide 2: Agenda
Agenda Transaction Highlights and Strategic Rationale Dave Ricks, Chairman and Chief Executive Officer Combination with Lilly Oncology Anne White, President, Lilly Oncology Loxo Oncology Portfolio Overview Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer and President, Lilly Research Labs Finan
Slide 3: Safe Harbor Provision
SAFE HARBOR PROVISION Soa. During this conference call, we anticipate making projections and forward-looking statements that are based ut actual results may differ materially due to various factors. For example: our results — alone or following the completion of this acquisition - may be affected by
Slide 4: Additional Information About the Acquisition and Where to Find It
ADDITIONAL INFORMATION ABOUT THE ACQUISITION AND WHERE TO FIND IT The tender offer for the outstanding shares of Loxo Oncology referenced in this ication has not yet This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell share
Slide 5: Strategic Rationale
STRATEGIC RATIONALE Loxo Oncology acquisition consistent with Lilly strategy Grow Revenue + Brings opportunity for multiple near-term launches, bolstering oncology franchise + Enhances growth prospects post-Alimta patent expiration + Contributes revenue in 2019 Create Long-Term Value + Consistent wi
Slide 6: Lilly Oncology Portfolio Enhanced
LILLY ONCOLOGY PORTFOLIO E Existing Lilly Oncology Pipeline as of January 4, 201 NHANCED 4 Not for promotional use @ chemicatenriy @ siotechenry NiLeX LOKO Additions * commercial Collaboration §
Slide 7: Loxo Oncology Portfolio
LOXO ONCOLOGY PORTFOLIO Highly selective, targeted cancer therapies for specific tumor mutations EARLY STAGE LATE STAGE REGULATORY PRECLINICAL DEVELOPMENT DEVELOPMENT SUBMISSION APPROVED VITRAKVI® (larotrectinib) - TRK Inhibitor, in collaboration with Bayer LOX0-292-¢. harboring RET-fusions or activ
Slide 8: Vitrakvi (larotrectinib)
VITRAKVI (LAROTRECTINIB) SELECTIVE ORAL TRK INHIBITOR IN COLLABORATION WITH BAYER") Lit, First in class NEJM publication February 2018 © FDA accelerated approval November 2018 © Clinical data in 55 patients with TRK fusion cancer © Submitted to EMA in August 2018 ITPCC September 2018 . © Poster with
Slide 9: LOXO-195
LOXO- 95 NEXT GENERATION TRK INHIBITOR IN COLLABORATION WITH BAYER") LL», KEY ATTRIBUTES DATA PRESENTATIONS Continuation of TRK franchise AACR-NCI-EORTC International Conference © Designed to address acquired resistance in patients on Molecular Targets and Cancer treated with TRK inhibitors Therapeu
Slide 10: LOXO-292
LOXO-292 HIGHLY SELECTIVE ORAL RET INHIBITOR, FULLY OWNED BY LOXO ONCOLOGY Lit, KEY ATTRIBUTES DATA PRESENTATIONS Potentially first-in-class, launching in 2020 ASCO June 2018 © Breakthrough Therapy designation for three | ° 82 patients with RET-altered cancers indications: — RET-fusion positive NSCL
Slide 11: LOXO-305
LOXO-305 HIGHLY SELECTIVE NON-COVALENT BTK INHIBITOR, FULLY OWNED BY LOXO ONCOLOGY A, ) KEY ATTRIBUTES DATA PRESENTATIONS Designed to address resistance and Society of Hematologic Oncology Annual intolerance in patients treated with Meeting September 2018 approved BTK inhibitors BTKis a validated th
Slide 12: Financial Implications: Offer Summary and Sources of Value
FINANCIAL IMPLICATIONS OFFER SUMMARY AND SOURCES OF VALUE OFFER SUMMARY All-cash tender at $235.00 per share Premium of approximately 68% to the closing share price on January 4, 2019 Aggregate purchase price of approximately $8.0 billion Net of Loxo Oncology cash and investments, purchase price of
Slide 13: Financial Implications: Financing Summary and Financial Impact
FINANCIAL IMPLICATIONS FINANCING SUMMARY AND FINANCIAL IMPACT FINANCING SUMMARY FINANCIAL IMPACT Combination of cash and debt to fund No changes to 2020 financial acquisition expectations Maintain flexibility to pursue licensing Impact to 2019 Financial Guidance to be and M&A within current credit r
Slide 14: Summary
Loxo Oncology is an exciting acquisition for Lilly, continuing our strategy of utilizing external innovation to augment internal research and development efforts Targeted therapies and genetic-based diagnostics offer significant potential to improve the lives of people with S U m m a ry advanced can
Slide 15: Question and Answer Session
Question and Answer Session